Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 3.2%

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shot up 3.2% during trading on Thursday . The stock traded as high as $8.14 and last traded at $8.06. 1,281,053 shares changed hands during mid-day trading, a decline of 79% from the average session volume of 6,082,450 shares. The stock had previously closed at $7.81.

Analyst Ratings Changes

Several research firms have recently commented on RXRX. KeyCorp lowered their target price on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Needham & Company LLC reissued a “buy” rating and issued a $17.00 target price on shares of Recursion Pharmaceuticals in a report on Tuesday, June 25th.

Recursion Pharmaceuticals Price Performance

The firm’s fifty day moving average price is $8.50 and its 200 day moving average price is $9.60.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.04. The company had revenue of $13.80 million for the quarter, compared to the consensus estimate of $11.10 million. Recursion Pharmaceuticals had a negative net margin of 765.90% and a negative return on equity of 79.96%. Recursion Pharmaceuticals’s revenue was up 14.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.34) earnings per share. As a group, research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.56 EPS for the current fiscal year.

Insider Activity at Recursion Pharmaceuticals

In related news, COO Tina Marriott sold 3,000 shares of the company’s stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $8.78, for a total transaction of $26,340.00. Following the sale, the chief operating officer now owns 535,457 shares of the company’s stock, valued at $4,701,312.46. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Recursion Pharmaceuticals news, COO Tina Marriott sold 3,000 shares of the business’s stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $8.78, for a total transaction of $26,340.00. Following the transaction, the chief operating officer now owns 535,457 shares in the company, valued at $4,701,312.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $8.48, for a total transaction of $97,070.56. Following the transaction, the director now owns 7,155,663 shares in the company, valued at approximately $60,680,022.24. The disclosure for this sale can be found here. Insiders have sold a total of 257,682 shares of company stock valued at $2,083,123 over the last 90 days. 15.75% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of RXRX. Benjamin F. Edwards & Company Inc. bought a new position in Recursion Pharmaceuticals during the first quarter valued at $26,000. National Bank of Canada FI increased its position in Recursion Pharmaceuticals by 90.9% during the fourth quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock valued at $31,000 after acquiring an additional 1,500 shares during the last quarter. First Horizon Advisors Inc. bought a new position in Recursion Pharmaceuticals during the fourth quarter valued at $47,000. GAMMA Investing LLC grew its holdings in shares of Recursion Pharmaceuticals by 1,588.4% in the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after purchasing an additional 6,036 shares during the last quarter. Finally, Midwest Financial Group LLC bought a new position in shares of Recursion Pharmaceuticals in the second quarter worth about $90,000. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.